| Literature DB >> 27042158 |
Suhel Kotwal1, Bryan Moon2, Patrick Lin2, Robert Satcher2, Valerae Lewis2.
Abstract
Humerus is a common site for malignant tumors. Advances in adjuvant therapies and reconstructive methods provide salvage of the upper limb with improved outcomes. Reports of limb salvage with total humeral replacement in extensive humeral tumors are sparse. We undertook a retrospective study of 20 patients who underwent total humeral endoprosthetic replacement as limb salvage following excision of extensile malignant tumor from 1990 to 2011. With an average followup of 42.9, functional and oncological outcomes were analyzed. Ten patients were still alive at the time of review. Mean estimated blood loss was 1131 mL and duration of surgery was 314 minutes. Deep infection was encountered in one patient requiring debridement while mechanical loosening of ulnar component was identified in one patient. Subluxation of prosthetic humeral head was noted in 3 patients. Mean active shoulder abduction was 12.5° and active flexion was 15°. Incompetence of abduction mechanism was the major determinant of poor active functional outcome. Mean elbow flexion was 103.5° with 30.5° flexion contracture in 10 patients with good and useful hand function. Average MSTS score was 71.5%. Total humeral replacement is a reliable treatment option in restoring mechanical stability and reasonable functional results without compromising patient survival, with low complication rate.Entities:
Year: 2016 PMID: 27042158 PMCID: PMC4799826 DOI: 10.1155/2016/6318060
Source DB: PubMed Journal: Sarcoma ISSN: 1357-714X
Figure 116-year-old male with telangiectatic osteosarcoma of the humeral shaft, treated with total humeral resection and endoprosthetic construction.
Demographics and surgical details.
| Case | Gender | Age | Diagnosis | Previous treatment | Plastic surgery | Ulna stem | EBL | DOS | LOS |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| 1 | M | 67 | Unclassified | Cx | IR + LDMF | Long | 850 | 347 | 13 |
| 2 | F | 11 | OS-osteoblastic | Cx | ER + LDMF | Short | 800 | 314 | 7 |
| 3 | M | 38 | CS | Cx | ER + LDMF | Long | 600 | 325 | 8 |
| 4 | F | 12 | OS | Cx | ER + LDMF | Short | 1075 | 301 | 5 |
| 5 | F | 70 | OS-high-grade surface | Cx, IM nail | IR | Short | 500 | 345 | 5 |
| 6 | F | 13 | ES | Cx | IR | Long | 1150 | 165 | 4 |
| 7 | F | 32 | OS-fibroblastic | Cx, IM nail | ER + LDMF | Short | 400 | 180 | 8 |
| 8 | F | 4 | OS-osteoblastic | Cx | ER | Short | 100 | 57 | 4 |
| 9 | M | 16 | OS-telangiectatic | Cx | IR | Long | 550 | 362 | 3 |
| 10 | M | 9 | OS-high-grade surface | Cx | IR | Short | 250 | 339 | 8 |
| 11 | F | 24 | OS chondroblastic | Cx | IR + LDMF | Long | 1000 | 469 | 9 |
|
| |||||||||
|
| |||||||||
| 12 | F | 46 | Breast | IR | Short | 4000 | 210 | 10 | |
| 13 | M | 57 | Thyroid | IR | Long | 1800 | 271 | 7 | |
| 14 | M | 69 | RCC | IR | Long | 1000 | 266 | 7 | |
| 15 | M | 59 | RCC | IM nail | IR | Short | 350 | 182 | 3 |
| 16 | M | 62 | RCC | IM nail | IR | Long | 400 | 653 | 9 |
| 17 | M | 65 | RCC | IR | Short | 6050 | 351 | 5 | |
| 18 | M | 66 | RCC | IR | Long | 900 | 394 | 2 | |
| 19 | F | 36 | ASPS | IR | Long | 600 | 513 | 31 | |
| 20 | F | 62 | RCC | Endoprosthesis (prox. humeral) | IR | Long | 250 | 237 | 14 |
Figure 2Implant survival.
Figure 3Patient survival.
Outcome.
| Case | Complications | Additional treatment | Follow-up (mos) | MSTS score (%) | ROM shoulder (degrees) | ROM elbow (degrees) | Recurrence | Status | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Abduction | Flexion | Flexion | Extension | |||||||
|
| ||||||||||
| 1 | Subluxation | 18 | 77 | 5 | 5 | 130 | 0 | N | DOD | |
| 2 | 16 | 77 | 0 | 0 | 100 | 20 | N | DOD | ||
| 3 | 52 | 95 | 0 | 0 | 90 | 20 | N | NED | ||
| 4 | 36 | 63 | 30 | 30 | 100 | 30 | N | DOD | ||
| 5 | Subluxation, loosening | 108 | 73 | 5 | 5 | 80 | 0 | N | NED | |
| 6 | Subluxation | 172 | 63 | 0 | 0 | 100 | 0 | N | NED | |
| 7 | Dislocation | Revision (67 mos) | 138 | 48 | 10 | 10 | 130 | 0 | N | NED |
| 8 | 27 | 100 | 110 | 110 | 100 | 40 | N | DOD | ||
| 9 | 48 | 73 | 40 | 40 | 130 | 0 | N | NED | ||
| 10 | 24 | 80 | NA | NA | 90 | 0 | N | NED | ||
| 11 | Subluxation | Revision (22 mos) | 22 | 66 | 10 | 10 | 110 | 5 | N | NED |
|
| ||||||||||
|
| ||||||||||
| 12 | Wound dehiscence | Wound revision (35 d) | 3 | 53 | 0 | 0 | 100 | 20 | N | DOD |
| 13 | 9 | 77 | 5 | 5 | 100 | 0 | N | AWD | ||
| 14 | 1 | 73 | NA | NA | NA | NA | N | DOD | ||
| 15 | RNP, infection, and subluxation | Irrigation & debridement | 46 | 40 | NA | NA | 100 | 30 | Y | DOD |
| 16 | 81 | 83 | 0 | 0 | 120 | 20 | N | AWD | ||
| 17 | RNP, subluxation | 18 | 67 | 0 | 0 | 110 | 10 | N | DOD | |
| 18 | Dislocation | Revision (2 days) | 7 | 53 | 0 | 0 | 120 | 60 | N | DOD |
| 19 | 7 | 82 | 0 | 0 | 30 | 0 | N | DOD | ||
| 20 | Subluxation | 24 | 87 | 10 | 10 | 110 | 20 | N | AWD | |
Perioperative parameters.
| Case | EBL (mL) | DOS (min) | LOS (days) |
|---|---|---|---|
|
| |||
| 1 | 850 | 347 | 13 |
| 2 | 800 | 314 | 7 |
| 3 | 600 | 325 | 8 |
| 4 | 1075 | 301 | 5 |
| 5 | 500 | 345 | 5 |
| 6 | 1150 | 165 | 4 |
| 7 | 400 | 180 | 8 |
| 8 | 100 | 57 | 4 |
| 9 | 550 | 362 | 3 |
| 10 | 250 | 339 | 8 |
| 11 | 1000 | 469 | 9 |
|
| |||
|
| |||
| 12 | 4000 | 210 | 10 |
| 13 | 1800 | 271 | 7 |
| 14 | 1000 | 266 | 7 |
| 15 | 350 | 182 | 3 |
| 16 | 400 | 653 | 9 |
| 17 | 6050 | 351 | 5 |
| 18 | 900 | 394 | 2 |
| 19 | 600 | 513 | 31 |
| 20 | 250 | 237 | 14 |
Figure 4
Figure 5